


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR ACCESS TO AN APPLICATION UNDER 37 CFR 1.14(e)

In re Application of

Application Number

09-062142

Filed

4-17-98

Art Unit

Examiner

Paper No. #6

Assistant Commissioner for Patents
Washington, DC 20231

1. ☐ I hereby request access under 37 CFR 1.14(e)(2) to the application file record of the above-identified ABANDONED Application, which is not within the file jacket of a pending Continued Prosecution Application (CPA) (37 CFR 1.53(d)) and is: (CHECK ONE)

☐ (A) referred to in:

United States Patent Application Publication No. 6153420, page _____, line _____,

United States Patent Number _____, column _____, line _____, or

an International Application which was filed on or after November 29, 2000 and which

designates the United States, WIPO Pub. No. _____, page _____, line _____.

☐ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11(b) or

1.14(e)(2)(i), i.e., Application No. _____, paper No. _____, page _____, line _____.

2. ☐ I hereby request access under 37 CFR 1.14(e)(1) to an application in which the applicant has filed an authorization to lay open the complete application to the public.

AC
Signature

12-16-02
Date

ADRIAN
Typed or printed name

FOR PTO USE ONLY	
RECEIVED	
Approved by: <u>[Signature]</u>	Initials: <u>[Signature]</u>
Unit: DEC 16 2002	



US006153420A

United States Patent [19]

Sheppard

[11] **Patent Number:** 6,153,420
 [45] **Date of Patent:** Nov. 28, 2000

[54] **SERINE PROTEASE POLYPEPTIDES AND MATERIALS AND METHODS FOR MAKING THEM**

[75] **Inventor:** Paul O. Sheppard, Redmond, Wash.

[73] **Assignee:** ZymoGenetics, Inc., Seattle, Wash.

[21] **Appl. No.:** 09/072,384

[22] **Filed:** May 4, 1998

Related U.S. Application Data

[63] Continuation-in-part of application No. 09/062,142, Apr. 17, 1998, abandoned

[60] Provisional application No. 60/044,185, Apr. 24, 1997.

[51] **Int. Cl.⁷** C12N 9/64; C12N 15/57; C12N 15/62; C12N 15/70; C12N 15/79

[52] **U.S. Cl.** 435/226; 435/69.1; 435/69.7; 435/252.3; 435/25.33; 435/320.1; 435/417; 536/23.2; 536/23.4

[58] **Field of Search** 435/226, 69.1, 435/69.7, 252.3, 252.33, 320.1, 417; 536/23.2, 23.4

[56] References Cited

U.S. PATENT DOCUMENTS

5,460,950	10/1995	Barr et al.	435/69.1
5,460,953	10/1995	Gerlitz et al.	435/226
5,804,410	9/1998	Yamaoka et al.	435/69.1
5,863,756	1/1999	Barr et al.	435/69.1

FOREIGN PATENT DOCUMENTS

95/14772 6/1965 WIPO.

OTHER PUBLICATIONS

Li, k., et al., GenBank nucleotide sequence Accession No. AF015287, "A novel serine protease from human umbilical vein endothelial cells, clone 10.16", 1997.

Clone ID 3655371, Incyte Pharmaceuticals, Inc., Oct. 6, 1997.

Clone ID 3655384, Incyte Pharmaceuticals, Inc., Oct. 6, 1997.

Clone ID 3656369, Incyte Pharmaceuticals, Inc., Oct. 6, 1997.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1995.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1995.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1995.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1995.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1997.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1997.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1997.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1997.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1997.

(List continued on next page.)

Primary Examiner—Ponnathapu Achutamurthy

Assistant Examiner—William W. Moore

Attorney, Agent, or Firm—Gary E. Parker

[57] ABSTRACT

A novel serine protease is disclosed. The protease comprises a sequence of amino acid residues that is at least 95% identical to SEQ ID NO:2 from Ile, residue 111, through Asn, residue 373. Also disclosed are polynucleotide molecules encoding the protease, expression vectors containing the polynucleotides, cultured cells containing the expression vectors, and methods of making the protease. The protease can be used, inter alia, within industrial processes to degrade unwanted proteins or alter the characteristics of protein-containing compositions.

24 Claims, No Drawings